The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure

The p53 protein has been extensively studied for its capacity to prevent proliferation of cells with a damaged genome. Surprisingly, however, our recent analysis of mice expressing a hyperactive mutant p53 that lacks the C-terminal domain revealed that increased p53 activity may alter genome maintenance. We showed that p53 downregulates genes essential for telomere metabolism, DNA repair, and centromere structure and that a sustained p53 activity leads to phenotypic traits associated with dyskeratosis congenita and Fanconi anemia. This downregulation is largely conserved in human cells, which suggests that our findings could be relevant to better understand processes involved in bone marrow failure as well as aging and tumor suppression.

[1]  D. M. Martin,et al.  Inappropriate p53 Activation During Development Induces Features of CHARGE Syndrome , 2014, Nature.

[2]  L. Attardi,et al.  p53 at a glance , 2010, Journal of Cell Science.

[3]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[4]  P. Fei,et al.  Fanconi Anemia Signaling and Cancer. , 2017, Trends in cancer.

[5]  W. Fok,et al.  p53 Mediates Failure of Human Definitive Hematopoiesis in Dyskeratosis Congenita , 2017, Stem cell reports.

[6]  Stephen J Chanock,et al.  Genetic variation, nucleotide diversity, and linkage disequilibrium in seven telomere stability genes suggest that these genes may be under constraint , 2005, Human mutation.

[7]  S. Volarevic,et al.  Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. , 2014, Biochimica et biophysica acta.

[8]  M. Kaufman,et al.  High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.

[9]  Stephen N. Jones,et al.  p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.

[10]  V. Rotter,et al.  A DNA binding domain is contained in the C-terminus of wild type p53 protein. , 1991, Nucleic acids research.

[11]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[12]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Toledo,et al.  Cancer: Three birds with one stone , 2009, Nature.

[14]  D. Hanahan,et al.  Mouse models for the study of telomerase. , 1997, Ciba Foundation symposium.

[15]  Manuel Serrano,et al.  The Hallmarks of Aging , 2013, Cell.

[16]  J. Bodalski,et al.  FANCONI'S ANAEMIA AND DYSKERATOSIS CONGENITA AS A SYNDROME. , 1963, Dermatologica.

[17]  F. Gage,et al.  Puma is required for p53-induced depletion of adult stem cells , 2010, Nature Cell Biology.

[18]  Xiaodong Qi,et al.  Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. , 2011, Blood.

[19]  S. Savage,et al.  The genomics of inherited bone marrow failure: from mechanism to the clinic , 2017, British journal of haematology.

[20]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[21]  P. Cahan,et al.  Poly(A)-specific ribonuclease (PARN) mediates 3′-end maturation of the telomerase RNA component , 2015, Nature Genetics.

[22]  H. Kiyokawa,et al.  Tumor-prone phenotype of the DDB2-deficient mice , 2005, Oncogene.

[23]  Eléonore Toufektchan,et al.  p53 downregulates the Fanconi anaemia DNA repair pathway , 2016, Nature Communications.

[24]  C. Harris,et al.  Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.

[25]  B. Liu,et al.  ROS and p53: a versatile partnership. , 2008, Free radical biology & medicine.

[26]  J. Espinosa,et al.  Mechanisms of transcriptional regulation by p53 , 2017, Cell Death and Differentiation.

[27]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[28]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[29]  Yie Liu,et al.  Fanconi anemia proteins in telomere maintenance. , 2016, DNA repair.

[30]  K. Engeland,et al.  p53 can repress transcription of cell cycle genes through a p21WAF1/CIP1-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements , 2012, Cell cycle.

[31]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[32]  R. DePinho,et al.  Telomeres and telomerase in cancer. , 2010, Carcinogenesis.

[33]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[34]  K. Offit,et al.  A Recessive Founder Mutation in Regulator of Telomere Elongation Helicase 1, RTEL1, Underlies Severe Immunodeficiency and Features of Hoyeraal Hreidarsson Syndrome , 2013, PLoS genetics.

[35]  M. Fischer,et al.  The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes , 2015, Nucleic acids research.

[36]  B. Honig,et al.  Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode , 2016, Nature.

[37]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[38]  G. Lozano Mouse models of p53 functions. , 2010, Cold Spring Harbor perspectives in biology.

[39]  L. Attardi,et al.  Deciphering p53 signaling in tumor suppression. , 2018, Current opinion in cell biology.

[40]  S. Lowe Activation of p53 by oncogenes. , 1999, Endocrine-related cancer.

[41]  V. Rotter p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Donehower,et al.  Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity , 2007, Mechanisms of Ageing and Development.

[43]  P. Chumakov,et al.  The antioxidant function of the p53 tumor suppressor , 2005, Nature Medicine.

[44]  Q. Zhan Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. , 2005, Mutation research.

[45]  G. Almouzni,et al.  Essential role for centromeric factors following p53 loss and oncogenic transformation , 2017, Genes & development.

[46]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[47]  M. E. Perry,et al.  mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation , 2003, Molecular and Cellular Biology.

[48]  H. Walden,et al.  The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. , 2014, Annual review of biophysics.

[49]  Vanesa Gottifredi,et al.  p53 Down-Regulates CHK1 through p21 and the Retinoblastoma Protein , 2001, Molecular and Cellular Biology.

[50]  G. Wahl,et al.  Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. , 2011, Genes & development.

[51]  I. Demuth,et al.  SNM1B/Apollo in the DNA damage response and telomere maintenance , 2017, Oncotarget.

[52]  P. Cahan,et al.  Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. , 2016, The Journal of clinical investigation.

[53]  K. Engeland,et al.  Timing of transcription during the cell cycle: Protein complexes binding to E2F, E2F/CLE, CDE/CHR, or CHR promoter elements define early and late cell cycle gene expression , 2016, Oncotarget.

[54]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[55]  M. Oren,et al.  The loss of mdm2 induces p53 mediated apoptosis , 2000, Oncogene.

[56]  J. Manfredi,et al.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein. , 2016, Trends in biochemical sciences.

[57]  M. Oren,et al.  p53 and ribosome biogenesis stress: The essentials , 2014, FEBS letters.

[58]  Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence , 2018, Cell Death & Disease.

[59]  A. Bertuch The molecular genetics of the telomere biology disorders , 2016, RNA biology.

[60]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[61]  E. Appella,et al.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Lozano,et al.  The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development , 2007, The Journal of pathology.

[63]  M. Kastan Commentary on "Participation of p53 Protein in the Cellular Response to DNA Damage". , 2016, Cancer research.

[64]  Sathish Kumar Mungamuri,et al.  p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes , 2013, Oncogene.

[65]  D. Broccoli,et al.  p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. , 1999, Science.

[66]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[67]  G. Wahl,et al.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Bourdon,et al.  Mutant mice lacking the p53 C-terminal domain model telomere syndromes. , 2013, Cell reports.

[69]  J. Soulier,et al.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. , 2012, Cell stem cell.

[70]  María A Blasco,et al.  Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.

[71]  C. Prives,et al.  Relevance of the p53–MDM2 axis to aging , 2017, Cell Death and Differentiation.

[72]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[73]  P. Saetrom,et al.  Cell cycle regulation of human DNA repair and chromatin remodeling genes. , 2015, DNA repair.

[74]  G. Lozano,et al.  Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development , 2007, Molecular and Cellular Biology.

[75]  V. J. Selmanowitz,et al.  Dyskeratosis congenita: relationship to Fanconi's anemia. , 1972, Blood.

[76]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[77]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[78]  K. Mohammad,et al.  Modulation of mammalian life span by the short isoform of p53. , 2004, Genes & development.

[79]  R. Yerushalmi,et al.  BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo , 2015, Oncotarget.

[80]  K. Engeland Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM , 2017, Cell Death and Differentiation.

[81]  P. May,et al.  Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.

[82]  V. Plagnol,et al.  Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. , 2015, The Journal of clinical investigation.

[83]  C. Schildkraut,et al.  FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres , 2017, Proceedings of the National Academy of Sciences.

[84]  B. Alter,et al.  VACTERL-H Association and Fanconi Anemia , 2012, Molecular Syndromology.

[85]  Sathish Kumar Mungamuri,et al.  The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo , 2013, Genes & development.

[86]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[87]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[88]  R. Tothill,et al.  Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors , 2008, Molecular Cancer Research.

[89]  Matthias Dobbelstein,et al.  p21/CDKN1A Mediates Negative Regulation of Transcription by p53* , 2003, Journal of Biological Chemistry.

[90]  G. Joksiċ,et al.  Dysfunctional telomeres in primary cells from Fanconi anemia FANCD2 patients , 2012, Genome Integrity.

[91]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[92]  P. Sung,et al.  Stress and DNA repair biology of the Fanconi anemia pathway. , 2014, Blood.

[93]  M. R. Murphy,et al.  PARN deadenylase is involved in miRNA-dependent degradation of TP53 mRNA in mammalian cells , 2015, Nucleic acids research.

[94]  F. Toledo,et al.  Ribosome biogenesis dysfunction leads to p53-mediated apoptosis and goblet cell differentiation of mouse intestinal stem/progenitor cells , 2015, Cell Death and Differentiation.

[95]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[96]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[97]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[98]  Christopher Y. Park,et al.  Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects , 2008, Nature Genetics.

[99]  C. Prives,et al.  Dysfunction of the MDM2/p53 axis is linked to premature aging. , 2017, The Journal of clinical investigation.

[100]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[101]  B. Tian,et al.  Positive and negative feedback loops in the p53 and mRNA 3′ processing pathways , 2013, Proceedings of the National Academy of Sciences.

[102]  J. Benítez,et al.  BRCA2 Acts as RAD51 Loader to Facilitate Telomere Replication and Capping , 2010, Nature Structural &Molecular Biology.

[103]  Yiming Zhu,et al.  A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models , 2018, eLife.

[104]  S. Jaber,et al.  Les liaisons dangereuses : p53, dyskératose congénitale et anémie de Fanconi , 2017 .

[105]  Richard C. Wang,et al.  Engineered telomere degradation models dyskeratosis congenita. , 2008, Genes & development.

[106]  L. Donehower Using mice to examine p53 functions in cancer, aging, and longevity. , 2009, Cold Spring Harbor perspectives in biology.

[107]  Björn Schumacher,et al.  p53 in the DNA-Damage-Repair Process. , 2016, Cold Spring Harbor perspectives in medicine.

[108]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[109]  S. Benchimol,et al.  From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: The telomere loss/DNA damage model of cell aging , 1996, Experimental Gerontology.

[110]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.